Crossmark

Rapid efficacy of efgartigimod for generalized myasthenia gravis patients in acute exacerbations/worsening: multicenter real-world retrospective study

Crossref DOI link: https://doi.org/10.1007/s00415-026-13695-3

Published Online: 2026-02-16

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lin, Jing

Chang, Ting

Xiao, Lianchen

Hu, Jinquan

Di, Li

Yang, Chunsheng

Wu, Yan

Jiang, Yan

Zhang, Juanjuan

Bu, Bitao

Li, Zhijun
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82371411)

Beijing Medical Award Foundation Award for Medical Sciences (YXJL-2024-0387-0085)

Beijing Life Oasis Public Service Center (P119-003)
License Information

Text and Data Mining valid from 2026-02-01

Version of Record valid from 2026-02-16
More Information

Article History

Received: 20 November 2025

Revised: 6 February 2026

Accepted: 7 February 2026

First Online: 16 February 2026

Declarations

:

: All authors claim that there are no conflicts of interest.

: The study has been approved by the Clinical Investigation Committee at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (Approval Number: TJ-IRB202407056) and conformed to the principles of the Declaration of Helsinki.

: Written or oral informed consent for the publication of this study was obtained from the patient and/or their family.

Document is current

Any future updates will be listed below